Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Preoperative serum CA 72.4 as prognostic factor of recurrence and death, especially at TNM stage II, for colorectal cancer

Authors: Daniel Ayude, Francisco Javier Rodríguez-Berrocal, José Ayude, Sonia Blanco-Prieto, Lorena Vázquez-Iglesias, Marta Vázquez-Cedeira, María Páez de la Cadena

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Nowadays, evaluation of colorectal cancer prognosis and decision-making for treatment continues to be based primarily on TNM tumour stage. Administration of adjuvant chemotherapy is especially challenging for stage II patients that can have very different disease-related outcomes. Therefore, more reliable prognostic markers need to be developed to improve the selection of stage II patients at high risk for recurrence. Our purpose is to assess the prognostic value of preoperative serum CA 72.4 to improve the risk stratification of CRC patients.

Methods

Preoperative sera collected from 71 unselected patients between January 1994 and February 1997 was assayed for CA 72.4 and CEA levels. Patients were followed-up for at least 30 months or until relapse. Survival curves were estimated by the Kaplan-Meier method and the prognostic value was determined using Log-Rank test and Cox regression analysis.

Results

Preoperative CA 72.4 levels above 7 U/mL correlate with a worse prognosis, with associated recurrence and death percentages exceeding the displayed by CEA. In a multivariate analysis, its combination with CEA proved the most important independent factor predicting survival. Remarkably, at stage II CA 72.4 also discriminates better than CEA those patients that will relapse or die from those with a favourable prognosis; however, CEA has not a negligible effect on survival.

Conclusions

The most outstanding finding of the present work is the correct classification of nearly every patient with bad prognosis (relapse or death) at TNM stage II when CEA and CA 72.4 are used altogether. This could improve the decision-making involved in the treatment of stage II colon cancer. Certainly further large-scale studies must be performed to determine whether CA 72.4 can be effectively used in the clinical setting.
Appendix
Available only for authorised users
Literature
1.
American Cancer Society: Cancer Facts & Figures 2011–13, p 4. 2011, Atlanta: American Cancer Society
2.
Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010, 46: 765-781. 10.1016/j.ejca.2009.12.014.CrossRefPubMed
3.
Xu F, Wang F, Di M, Huang Q, Wang M, Hu H, Jin Y, Dong J, Lai M: Classification based on the combination of molecular and pathologic predictors is superior to molecular classification on prognosis in colorectal carcinoma. Clin Cancer Res. 2007, 13: 5082-5088. 10.1158/1078-0432.CCR-07-0597.CrossRefPubMed
4.
Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009, 58: 90-96. 10.1136/gut.2008.155473.CrossRefPubMed
5.
Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA: ICBP Module 1 Working Group: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011, 377: 127-138. 10.1016/S0140-6736(10)62231-3.CrossRefPubMedPubMedCentral
6.
Lang K, Korn JR, Lee DW, Lines LM, Earle CC, Menzin J: Factors associated with improved survival among older colorectal cancer patients in the US: a population-based analysis. BMC Cancer. 2009, 9: 227-10.1186/1471-2407-9-227.CrossRefPubMedPubMedCentral
7.
Greene FL, Sobin LH: The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin. 2008, 58: 180-190. 10.3322/CA.2008.0001.CrossRefPubMed
8.
Sobin C, Wittikind C: TNM classification of malignant tumors. 2010, London: Wiley and Sons Inc. New York, 7
9.
Gangadhar T, Schilsky RL: Medscape: Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010, 7: 318-325. 10.1038/nrclinonc.2010.62.CrossRefPubMed
10.
O’Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004, 96: 1420-1425. 10.1093/jnci/djh275.CrossRefPubMed
11.
Saltz LB: Adjuvant therapy for colon cancer. Surg Oncol Clin N Am. 2010, 19: 819-827. 10.1016/j.soc.2010.07.005.CrossRefPubMed
12.
André T, Afchain P, Barrier A, Blanchard P, Larsen AK, Tournigand C, Louvet C, de Gramont A: Current status of adjuvant therapy for colon cancer. Gastrointest Cancer Res. 2007, 1: 90-97.PubMedPubMedCentral
13.
O’Connell MJ: Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. J Clin Oncol. 2009, 27: 3082-3084. 10.1200/JCO.2009.22.2919.CrossRefPubMed
14.
Marshall JL: Risk assessment in Stage II colorectal cancer. Oncology (Williston Park). 2010, 24 (1 Suppl 1): 9-13.
15.
Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F, Casaldi V, Wappner G, Abbolito MR, Greiner JW, et al: CA 72–4 serum marker-A new tool in the management of carcinoma patients. Cancer invest. 1995, 13: 227-238. 10.3109/07357909509011692.CrossRefPubMed
16.
Reiter W, Stieber P, Reuter C, Nagel D, Cramer C, Pahl H, Fateh-Moghadam A: Prognostic value of preoperative serum levels of CEA, CA 19–9 and CA 72–4 in gastric carcinoma. Anticancer Res. 1997, 17: 2903-2906.PubMed
17.
Marelli D, Pinto E, De S, Farnetani M, Garosi L, Roviello F: Clinical Utility of CEA, CA 19–9, and CA 72–4 in the follow-up of patients with resectable gastric cancer. Am J Surg. 2001, 181: 16-19. 10.1016/S0002-9610(00)00549-3.CrossRef
18.
Aloe S, D’Alessandro R, Spila A, Ferroni P, Basili S, Palmirotta R, Carlini M, Graziano F, Mancini R, Mariotti S, Cosimelli M, Roselli M, Guadagni F: Prognostic value of serum and tumor tissue CA 72–4 content in gastric cancer. Int J Biol Markers. 2003, 18: 21-27.PubMed
19.
Fletcher RH: Carcinoembryonic antigen. Ann Intern Med. 1986, 104: 66-73. 10.7326/0003-4819-104-1-66.CrossRefPubMed
20.
Wang JY, Tang R, Chiang JM: Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum. 1994, 37: 272-277. 10.1007/BF02048166.CrossRefPubMed
21.
Carpelan-Holmström M, Hanglund C, Lundin J, Alfthan H, Stenman UH, Roberts PJ: Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polpeptide antigen in colorectal cancer. Br J Cancer. 1996, 74: 925-929. 10.1038/bjc.1996.458.CrossRefPubMedPubMedCentral
22.
Hermanek P, Sobin LH: UICC TNM Clasification of malignant tumours: Colon & Rectum. 4th ed, 2nd revision. 1992, London: Springer, 52-56.
23.
Takagawa T, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, Osada S, Ichikawa Y, Shimada H: Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Sug Oncol. 2008, 15: 3433-3439. 10.1245/s10434-008-0168-8.CrossRef
24.
Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Järvinen HJ, Haglund C: Serum HCG beta, CA 72–4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer. 2002, 101: 545-548. 10.1002/ijc.90009.CrossRefPubMed
25.
Fernández-Rodríguez J, Ayude D, Páez De La Cadena M, Martínez-Zorzano VS, De Carlos A, Caride-Castro A, De Castro G, Rodríguez-Berrocal FJ: Alpha-L-fucosidase enzyme in the prediction of colorectal cancer patients at high risk of tumor recurrence. Cancer Detec Prev. 2000, 24: 143-149.PubMed
26.
Ayude D, Páez De La Cadena M, Martínez-Zorzano VS, Fernáncez-Briera A, Rodríguez-Berrocal FJ: Preoperative serum alpha-L-fucosidase activity as prognostic marker in colorectal cancer. Oncology. 2003, 64: 36-45. 10.1159/000066521.CrossRefPubMed
27.
Feijoo-Carnero C, Rodríguez-Berrocal FJ, Paez De La Cadena M, Ayude D, De Carlos A, Martínez-Zorzano VS: Clinical significance of preoperative serum sialic acid levels in colorectal cancer: Utility in the detection of patients at high risk of tumor recurrence. Int J Biol Markers. 2004, 19: 38-45.PubMed
28.
Desch CE, Benson AB, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Pfister DG, Virgo KS, Petrelli NJ: American Society of Clinical Oncology: Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005, 23: 8512-8519. 10.1200/JCO.2005.04.0063.CrossRefPubMed
29.
Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O: Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007, 43: 1348-1360. 10.1016/j.ejca.2007.03.021.CrossRefPubMed
30.
Lindmark G, Kressner U, Bergström R, Glimelius B: Limited clinical significance of the serum tumour marker CA 72–4 in colorectal cancer. Anticancer Res. 1996, 16: 895-898.PubMed
31.
Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005, 23: 609-618.CrossRefPubMed
32.
Lanza G, Gafa R, Santini A, Maestri I, Guerzoni L, Cavazzini L: Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol. 2006, 24: 2359-2367. 10.1200/JCO.2005.03.2433.CrossRefPubMed
33.
Funaioli C, Pinto C, Mutri V, Di Fabio F, Ceccarelli C, Martoni AA: Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value?. Clin Colorectal Cancer. 2006, 6: 38-45. 10.3816/CCC.2006.n.019.CrossRefPubMed
34.
Zlobec I, Minoo P, Baumhoer D, Baker K, Terracciano L, Jass JR, Lugli A: Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer. 2008, 112: 495-502. 10.1002/cncr.23208.CrossRefPubMed
35.
Zlobec I, Baker K, Terracciano LM, Lugli A: RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis. Clin Cancer Res. 2008, 14: 3798-3806. 10.1158/1078-0432.CCR-07-5103.CrossRefPubMed
36.
Uen YH, Lin SR, Wu DC, Su YC, Wu JY, Cheng TL, Chi CW, Wang JY: Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann Surg. 2007, 246: 1040-1046. 10.1097/SLA.0b013e318142d918.CrossRefPubMed
37.
Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G: Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev. 2009, 35: 201-209. 10.1016/j.ctrv.2008.10.006.CrossRefPubMed
38.
Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A. 2008, 105: 19432-19437. 10.1073/pnas.0806674105.CrossRefPubMedPubMedCentral
39.
Thorsteinsson M, Jess P: The clinical significance of circulating tumor cells in non-metastatic colorectal cancer A review. Eur J Surg Oncol. 2011, 37: 459-465. 10.1016/j.ejso.2011.01.025.CrossRefPubMed
40.
Kerr D, Gray R, Quirke P, et al: A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study [abstract 4000]. J Clin Oncol. 2009, 27 (suppl): 15s-
Metadata
Title
Preoperative serum CA 72.4 as prognostic factor of recurrence and death, especially at TNM stage II, for colorectal cancer
Authors
Daniel Ayude
Francisco Javier Rodríguez-Berrocal
José Ayude
Sonia Blanco-Prieto
Lorena Vázquez-Iglesias
Marta Vázquez-Cedeira
María Páez de la Cadena
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-543

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels

Research article

Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivomouse colon cancer model

Research article

Incidence of pneumonia and risk factors among patients with head and neck cancer undergoing radiotherapy

Study protocol

Early rehabilitation of cancer patients – a randomized controlled intervention study

Research article

Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer

Research article

St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits